Kalaris Therapeutics, Inc. (KLRS)
| Market Cap | 96.12M +115.0% |
| Revenue (ttm) | n/a |
| Net Income | -44.10M |
| EPS | -2.18 |
| Shares Out | 23.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 395,114 |
| Open | 3.950 |
| Previous Close | 4.000 |
| Day's Range | 3.530 - 4.050 |
| 52-Week Range | 2.140 - 11.880 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 18.71 (+363.12%) |
| Earnings Date | Aug 12, 2026 |
About KLRS
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeut... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for KLRS stock is "Buy." The 12-month stock price target is $18.71, which is an increase of 363.12% from the latest price.
News
Kalaris Therapeutics appoints Liisa Bayko as CFO
Kalaris Therapeutics (KLRS) announced the appointment of Liisa Bayko as CFO. She most recently served as managing director and senior biotechnology analyst at Evercore ISI.
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
Strategic finance leader with over 20+ years of experience in the biotechnology space CFO hire bolsters Kalaris' leadership team and supports continued growth of the company as it enrolls its Phase 1b...
Why Is Kalaris Therapeutics (KLRS) Up Today?
Kalaris Therapeutics stock rallied after the company provided investors with updated clinical trial data.
Kalaris Therapeutics reports additional data from ascending dose trial of TH103
Kalaris Therapeutics (KLRS) announced additional data from its Phase 1a single ascending dose trial of TH103 in neovascular age-related macular degeneration. Data from the expanded cohorts build on pr...
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts
Kalaris Therapeutics Slides: Study update presentation
Kalaris Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 17, 2026.
Kalaris Appoints Laurie Keating to Board of Directors
Highly experienced biotechnology executive and board member will assist Kalaris in achieving its next phase of growth Highly experienced biotechnology executive and board member will assist Kalaris in...
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
BERKELEY HEIGHTS, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commerciali...
Kalaris Therapeutics initiated with a Buy at TD Cowen
TD Cowen analyst Tara Bancroft initiated coverage of Kalaris Therapeutics (KLRS) with a Buy rating and no price target The firm says the company’s TH103 is a “differentiated” anti-VEGF by…
Kalaris to Present at Clinical Trials at the Summit 2026
BERKELEY HEIGHTS, N.J., June 12, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commerciali...
Wedbush bullish on Kalaris Therapeutics, initiates with an Outperform
As previously reported, Wedbush initiated coverage of Kalaris Therapeutics (KLRS) with an Outperform rating and $17 price target The firm believes that the lead candidate TH103, a novel anti-VEGF ther...
Kalaris Therapeutics initiated with an Outperform at Wedbush
Wedbush initiated coverage of Kalaris Therapeutics (KLRS) with an Outperform rating and $17 price target
Kalaris Therapeutics price target lowered to $25 from $26 at Citizens
Citizens analyst Jonathan Wolleben lowered the firm’s price target on Kalaris Therapeutics (KLRS) to $25 from $26 and keeps an Outperform rating on the shares. Kalaris has completed manufacturing impr...
Kalaris Therapeutics reports Q1 EPS (46c), consensus (52c)
“I am happy to report that new batches of clinical material have been manufactured and are undergoing packaging and labeling, and we are currently screening patients for dosing in our…
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates
Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support upcoming dosing; preliminary data anticipated in 1H 2027 Planned Phase 3 c...
Kalaris Therapeutics Earnings release: Q1 2026
Kalaris Therapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Kalaris Therapeutics Quarterly report: Q1 2026
Kalaris Therapeutics has published its Q1 2026 quarterly earnings report on May 12, 2026.
Kalaris Therapeutics Proxy statement: Proxy filing
Kalaris Therapeutics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Kalaris Therapeutics Proxy statement: Proxy filing
Kalaris Therapeutics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Kalaris Therapeutics initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of Kalaris Therapeutics (KLRS) with an Overweight rating and $14 price target Kalaris is a clinical-stage biotech company developing TH103 for neovascular and exudati...
Kalaris Therapeutics Registration statement: Registration filing
Kalaris Therapeutics filed a registration statement on April 3, 2026, providing details about a securities offering with the SEC.
Kalaris Therapeutics Registration statement: Registration filing
Kalaris Therapeutics filed a registration statement on April 3, 2026, providing details about a securities offering with the SEC.
Kalaris Therapeutics reports FY25 EPS ($2.85), consensus ($3.70)
“This past year was truly transformational for Kalaris,” said Andrew Oxtoby, Chief Executive Officer of Kalaris Therapeutics (KLRS). “Following our initial listing as a public company in March 2025, w...
Kalaris Therapeutics sees cash runway into 4Q27
As of December 31, 2025, Kalaris had cash, cash equivalents and marketable securities of $118.0 million, compared with cash and cash equivalents of $1.6 million as of December 31, 2024.
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; preliminary data from ongoing Phase 1b/2 study expected in 1H 2027